Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice

Journal of Immunology

Volumn 187, Issue 6, 2011, Pages 3413-3421

  Lichtnekert, Julia ^a   Rupanagudi, Khader Valli ^a   Kulkarni, Onkar P ^a   Darisipudi, Murthy Narayana ^a   Allam, Ramanjaneyulu ^a,b   Anders, Hans Joachim ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; DROTRECOGIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; RHEUMATOID FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG MECHANISM; FEMALE; HUMORAL IMMUNITY; LUNG DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MACROPHAGE; MOUSE; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SKIN LUPUS ERYTHEMATOSUS; SPLEEN; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AUTOANTIBODIES; CELL SEPARATION; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MICE; MICE, INBRED MRL LPR; PROTEIN C; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 80053086272     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1101125     Document Type: Article

References (41)

1. Rahman, A., and D. A. Isenberg. 2008. Systemic lupus erythematosus. N. Engl. J. Med. 358: 929-939. (Pubitemid 351397092)
2. Appel, G. B., G. Contreras, M. A. Dooley, E. M. Ginzler, D. Isenberg, D. Jayne, L. S. Li, E. Mysler, J. Sánchez-Guerrero, N. Solomons, D. Wofsy; Aspreva Lupus Management Study Group. 2009. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 20: 1103-1112.
3. Xu, J., N. L. Esmon, and C. T. Esmon. 1999. Reconstitution of the human endothelial cell protein C receptor with thrombomodulin in phosphatidylcholine vesicles enhances protein C activation. J. Biol. Chem. 274: 6704-6710. (Pubitemid 29111091)
4. Esmon, C. T. 2003. The protein C pathway. Chest 124: 26S-32S. (Pubitemid 37128433)
5. Sarangi, P. P., H. W. Lee, and M. Kim. 2010. Activated protein C action in inflammation. Br. J. Haematol. 148: 817-833.
6. Levi, M., and T. Van der Poll. 2007. Recombinant human activated protein C: current insights into its mechanism of action. Crit. Care 11(Suppl 5): S3.
7. Bernard, G. R., J. L. Vincent, P. F. Laterre, S. P. LaRosa, J. F. Dhainaut, A. Lopez-Rodriguez, J. S. Steingrub, G. E. Garber, J. D. Helterbrand, E. W. Ely, C. J. Fisher Jr.; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. 2001. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344: 699-709. (Pubitemid 32204987)
8. Mosnier, L. O., B. V. Zlokovic, and J. H. Griffin. 2007. The cytoprotective protein C pathway. Blood 109: 3161-3172. (Pubitemid 46572500)
9. Whitmont, K., I. Reid, S. Tritton, L. March, M. Xue, M. Lee, G. Fulcher, P. Sambrook, E. Slobedman, A. Cooper, and C. Jackson. 2008. Treatment of chronic leg ulcers with topical activated protein C. Arch. Dermatol. 144: 1479-1483.
10. Jackson, C., K. Whitmont, S. Tritton, L. March, P. Sambrook, and M. Xue. 2008. New therapeutic applications for the anticoagulant, activated protein C. Expert Opin. Biol. Ther. 8: 1109-1122.
11. Han, M. H., S. I. Hwang, D. B. Roy, D. H. Lundgren, J. V. Price, S. S. Ousman, G. H. Fernald, B. Gerlitz, W. H. Robinson, S. E. Baranzini, et al. 2008. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 451: 1076-1081. (Pubitemid 351317445)
12. Neyrinck, A. P., K. D. Liu, J. P. Howard, and M. A. Matthay. 2009. Protective mechanisms of activated protein C in severe inflammatory disorders. Br. J. Pharmacol. 158: 1034-1047.
13. Isermann, B., I. A. Vinnikov, T. Madhusudhan, S. Herzog, M. Kashif, J. Blautzik, M. A. Corat, M. Zeier, E. Blessing, J. Oh, et al. 2007. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat. Med. 13: 1349-1358. (Pubitemid 350073598)
14. Scaldaferri, F., M. Sans, S. Vetrano, C. Graziani, R. De Cristofaro, B. Gerlitz, A. Repici, V. Arena, A. Malesci, J. Panes, et al. 2007. Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease. J. Clin. Invest. 117: 1951-1960. (Pubitemid 47036329)
15. Patole, P. S., R. D. Pawar, J. Lichtnekert, M. Lech, O. P. Kulkarni, A. Ramanjaneyulu, S. Segerer, and H. J. Anders. 2007. Coactivation of Toll-like receptor-3 and -7 in immune complex glomerulonephritis. J. Autoimmun. 29: 52-59. (Pubitemid 47016916)
16. Austin, H. A., III, L. R. Muenz, K. M. Joyce, T. T. Antonovych, and J. E. Balow. 1984. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int. 25: 689-695.
17. Allam, R., R. D. Pawar, O. P. Kulkarni, V. Hornung, G. Hartmann, S. Segerer, S. Akira, S. Endres, and H. J. Anders. 2008. Viral 59-triphosphate RNA and non- CpG DNA aggravate autoimmunity and lupus nephritis via distinct TLRindependent immune responses. Eur. J. Immunol. 38: 3487-3498.
18. Kulkarni, O., R. D. Pawar, W. Purschke, D. Eulberg, N. Selve, K. Buchner, V. Ninichuk, S. Segerer, V. Vielhauer, S. Klussmann, and H. J. Anders. 2007. Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL- (Fas)lpr mice. J. Am. Soc. Nephrol. 18: 2350-2358. (Pubitemid 47203851)
19. Lech, M., V. Skuginna, O. P. Kulkarni, J. Gong, T. Wei, R. W. Stark, C. Garlanda, A. Mantovani, and H. J. Anders. 2010. Lack of SIGIRR/TIR8 aggravates hydrocarbon oil-induced lupus nephritis. J. Pathol. 220: 596-607.
20. Steinmetz, O. M., J. E. Turner, H. J. Paust, M. Lindner, A. Peters, K. Heiss, J. Velden, H. Hopfer, S. Fehr, T. Krieger, et al. 2009. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis. J. Immunol. 183: 4693-4704.
21. Biesecker, G., S. Katz, and D. Koffler. 1981. Renal localization of the membrane attack complex in systemic lupus erythematosus nephritis. J. Exp. Med. 154: 1779-1794. (Pubitemid 12205587)
22. Pego-Reigosa, J. M., D. A. Medeiros, and D. A. Isenberg. 2009. Respiratory manifestations of systemic lupus erythematosus: old and new concepts. Best Pract. Res. Clin. Rheumatol. 23: 469-480.
23. Ohnmacht, C., A. Pullner, S. B. King, I. Drexler, S. Meier, T. Brocker, and D. Voehringer. 2009. Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity. J. Exp. Med. 206: 549-559.
24. Teichmann, L. L., M. L. Ols, M. Kashgarian, B. Reizis, D. H. Kaplan, and M. J. Shlomchik. 2010. Dendritic cells in lupus are not required for activation of T and B cells but promote their expansion, resulting in tissue damage. Immunity 33: 967-978.
25. Wang, Y., M. Thiyagarajan, N. Chow, I. Singh, H. Guo, and T. P. Davis, and B. V. Zlokovic. 2009. Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity. Stroke 40: 1864-1869.
26. Xu, J., X. Zhang, R. Pelayo, M. Monestier, C. T. Ammollo, F. Semeraro, F. B. Taylor, N. L. Esmon, F. Lupu, and C. T. Esmon. 2009. Extracellular histones are major mediators of death in sepsis. Nat. Med. 15: 1318-1321.
27. Griffin, JH, JA Fernaaposndez, AJ Gale, and LO Mosnier. 2007. Activated protein C. J. Thromb. Haemost. 5(Suppl 1): 73-80. (Pubitemid 46958820)
28. Yan, S. B., J. D. Helterbrand, D. L. Hartman, T. J. Wright, and G. R. Bernard. 2001. Low levels of protein C are associated with poor outcome in severe sepsis. Chest 120: 915-922. (Pubitemid 32885469)
29. Fisher, C. J., Jr., and S. B. Yan. 2000. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit. Care Med. 28(9 Suppl): S49-S56.
30. Cao, C., Y. Gao, Y. Li, T. M. Antalis, F. J. Castellino, and L. Zhang. 2010. The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b. J. Clin. Invest. 120: 1971-1980.
31. Brueckmann, M., U. Hoffmann, L. De Rossi, H. M. Weiler, V. Liebe, S. Lang, J. J. Kaden, M. Borggrefe, K. K. Haase, and G. Huhle. 2004. Activated protein C inhibits the release of macrophage inflammatory protein -1-alpha from THP-1 cells and from human monocytes. Cytokine 26: 106-113. (Pubitemid 38596920)
32. White, B., M. Schmidt, C. Murphy, W. Livingstone, D. O'Toole, M. Lawler, L. O'Neill, D. Kelleher, H. P. Schwarz, and O. P. Smith. 2000. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kB (NF-kappaB) and tumor necrosis factor a (TNF-a) production in the THP-1 monocytic cell line. Br. J. Haematol. 110: 130-134. (Pubitemid 30625601)
33. Stephenson, D. A., L. J. Toltl, S. Beaudin, and P. C. Liaw. 2006. Modulation of monocyte function by activated protein C, a natural anticoagulant. J. Immunol. 177: 2115-2122. (Pubitemid 44200969)
34. Kulkarni, O. P., S. G. Sayyed, C. Kantner, M. Ryu, M. Schnurr, M. Saaposrdy, J. Leban, R. Jankowsky, A. Ammendola, R. Doblhofer, and H. J. Anders. 2010. 4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice. Am. J. Pathol. 176: 2840-2847.
35. Kessenbrock, K., M. Krumbholz, U. Schönermarck, W. Back, W. L. Gross, Z. Werb, H. J. Gröne, V. Brinkmann, and D. E. Jenne. 2009. Netting neutrophils in autoimmune small-vessel vasculitis. Nat. Med. 15: 623-625.
36. Goodnow, C. C. 2007. Multistep pathogenesis of autoimmune disease. Cell 130: 25-35. (Pubitemid 47031326)
37. Guiducci, C., M. Gong, Z. Xu, M. Gill, D. Chaussabel, T. Meeker, J. H. Chan, T. Wright, M. Punaro, S. Bolland, et al. 2010. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 465: 937-941.
38. Kerschen, E., I. Hernandez, M. Zogg, S. Jia, M. J. Hessner, J. A. Fernandez, J. H. Griffin, C. S. Huettner, F. J. Castellino, and H. Weiler. 2010. Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice. J. Clin. Invest. 120: 3167-3178.
39. Yang, J., Y. Chu, X. Yang, D. Gao, L. Zhu, X. Yang, L. Wan, and M. Li. 2009. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 60: 1472-1483.
40. Kulkarni, O., D. Eulberg, N. Selve, S. Zöllner, R. Allam, R. D. Pawar, S. Pfeiffer, S. Segerer, S. Klussmann, and H. J. Anders. 2009. Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice. J. Pharmacol. Exp. Ther. 328: 371-377.
41. Abraham, E., P. F. Laterre, R. Garg, H. Levy, D. Talwar, B. L. Trzaskoma, B. François, J. S. Guy, M. Brückmann, A. Rea-Neto, et al; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. 2005. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N. Engl. J. Med. 353: 1332-1341. (Pubitemid 41362701)